UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

Cancer, 2019-03, Vol.125 (6), p.892-901

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3327-3334

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

The lancet oncology, 2015-07, Vol.16 (7), p.830-838

2015

Link zum Volltext

Verfügbarkeit prüfen

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

The lancet oncology, 2015-02, Vol.16 (2), p.141-151

2015

Link zum Volltext

Verfügbarkeit prüfen

Impact of EGFR Inhibitor in Non―Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

JNCI : Journal of the National Cancer Institute, 2013-05, Vol.105 (9), p.595-605

2013

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

The lancet oncology, 2010-08, Vol.11 (8), p.733-740

2010

Link zum Volltext

Verfügbarkeit prüfen

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

The lancet oncology, 2012-05, Vol.13 (5), p.539-548

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-03, Vol.29 (8), p.1059-1066

2011

Link zum Volltext

Verfügbarkeit prüfen

Applying Stimulus–Organism–Response Theory to Explore the Effects of Augmented Reality on Consumer Purchase Intention for Teenage Fashion Hair Dyes

Sustainability (Basel, Switzerland), 2024-03, Vol.16 (6), p.2537

2024

Link zum Volltext

Verfügbarkeit prüfen

A comprehensive quality improvement model: integrating internal and external information

Total quality management & business excellence, 2022-04, Vol.33 (5-6), p.548-565

2022

Link zum Volltext

Verfügbarkeit prüfen

Contrast enhancement by automatic and parameter-free piecewise linear transformation for color images

IEEE transactions on consumer electronics, 2008-05, Vol.54 (2), p.213-219

2008

Link zum Volltext
Volltext

Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs

International journal of molecular sciences, 2022-09, Vol.23 (19), p.11353

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer

PloS one, 2022-04, Vol.17 (4), p.e0267362-e0267362

2022

Link zum Volltext

Verfügbarkeit prüfen

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma

Oncotarget, 2017-10, Vol.8 (58), p.98384-98393

2017

Link zum Volltext

Verfügbarkeit prüfen

The effects of pad geometry and material properties on the biomechanical effectiveness of 26 commercially available hip protectors

Journal of biomechanics, 2011-10, Vol.44 (15), p.2627-2635

2011

Link zum Volltext

Verfügbarkeit prüfen

An evaluation instrument and strategy implications of service attributes in LOHAS restaurants

International journal of contemporary hospitality management, 2019-01, Vol.31 (1), p.194-216

2019

Link zum Volltext

Verfügbarkeit prüfen

Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice

Current oncology (Toronto), 2022-03, Vol.29 (3), p.2154-2164

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Cancer science, 2018-09, Vol.109 (9), p.2852-2862

2018

Link zum Volltext

Verfügbarkeit prüfen

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

Clinical cancer research, 2005-05, Vol.11 (10), p.3750-3757

2005

Link zum Volltext

Verfügbarkeit prüfen

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Journal of thoracic oncology, 2014-02, Vol.9 (2), p.154-162

2014

Link zum Volltext

Verfügbarkeit prüfen

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

International journal of clinical oncology, 2021-05, Vol.26 (5), p.841-850

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 647

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(560)
Mit Volltextzugriff
(623)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(434)
Life Sciences & Biomedicine
(319)
Humans
(256)
Male
(188)
Female
(176)
Oncology
(147)
Middle Aged
(142)
Aged
(140)
Adult
(116)
Technology
(100)
Lung Neoplasms - Drug Therapy
(96)
Aged, 80 And Over
(80)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(79)
Biological And Medical Sciences
(78)
Medical Sciences
(70)
Lung Neoplasms - Pathology
(65)
Physical Sciences
(56)
Chemotherapy
(55)
Carcinoma, Non-Small-Cell Lung - Pathology
(51)
Treatment Outcome
(50)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Thoracic Oncology
(38)
Journal Of Clinical Oncology
(22)
Lung Cancer
(22)
Cancer Research
(15)
Plos One
(13)
Japanese Journal Of Clinical Oncology
(9)
Journal Of Microbiology, Immunology And Infection
(9)
Chest
(8)
Oncotarget
(8)
Intermetallics
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Impact of EGFR Inhibitor in Non―Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Applying Stimulus–Organism–Response Theory to Explore the Effects of Augmented Reality on Consumer Purchase Intention for Teenage Fashion Hair Dyes

A comprehensive quality improvement model: integrating internal and external information

Contrast enhancement by automatic and parameter-free piecewise linear transformation for color images

Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma

The effects of pad geometry and material properties on the biomechanical effectiveness of 26 commercially available hip protectors

An evaluation instrument and strategy implications of service attributes in LOHAS restaurants

Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice

Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

Suchergebnisse filtern